8-K: Skye Bioscience Announces Auditor Transition and Shareholder Meeting Outcomes

Skye Bioscience, Inc. reported a change in its independent registered public accounting firm from Marcum LLP to CBIZ CPAs P.C. and detailed the results of its 2025 Annual Meeting of Stockholders, including the re-election of directors and approval of executive compensation.

Summary

• Skye Bioscience, Inc. changed its independent registered public accounting firm from Marcum LLP to CBIZ CPAs P.C., effective June 9, 2025, following CBIZ CPAs' acquisition of Marcum's attest business.
• Marcum's audit reports for fiscal years ended December 31, 2024, and 2023 contained no adverse opinions, disclaimers, or qualifications, and there were no disagreements or reportable events with the company.
• The company held its 2025 Annual Meeting of Stockholders on June 6, 2025, with 25,472,892 shares present or represented by proxy, representing 82.2% of the 30,974,558 outstanding shares entitled to vote, establishing a quorum.
• Stockholders re-elected all six nominated directors—Paul Grayson, Deborah Charych, Punit Dhillon, Annalisa Jenkins, Karen Smith, and Andrew J. Schwab—for a one-year term.
• The selection of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified by stockholders with 25,418,814 votes For, 17,402 Against, and 36,676 Abstain, prior to Marcum's subsequent resignation.
• The compensation of named executive officers was approved on an advisory basis with 17,064,084 votes For, 2,736,116 Against, 63,994 Abstain, and 5,608,698 Broker Non-Votes.
• Stockholders approved an annual frequency for future advisory votes on executive compensation, with 18,980,041 votes for a 1-Year frequency, leading the Board to adopt this policy until the next frequency vote expected at the 2031 annual meeting.

Sentiment

Score: 7

Explanation: The document reports routine corporate governance matters and an auditor change due to an acquisition, with no negative financial or operational news. All shareholder proposals passed with strong support, indicating stability and alignment. The auditor change was not due to any issues with the company's financials or practices, which is a positive sign.

Positives

• All six nominated directors were successfully re-elected by stockholders, indicating stability in the company's leadership.
• The ratification of the independent auditor (Marcum, prior to the change) passed overwhelmingly, demonstrating strong shareholder confidence in the audit process.
• Executive compensation was approved on an advisory basis, suggesting shareholder alignment with current compensation practices.
• The company's decision to conduct annual advisory votes on executive compensation aligns with the strong preference expressed by stockholders, enhancing corporate governance.
• The change in auditor was due to an acquisition of Marcum's attest business by CBIZ CPAs, not due to disagreements or adverse findings, indicating a smooth and non-contentious transition.

Future Outlook

The Board of Directors has determined that Skye Bioscience, Inc. will conduct future stockholder advisory votes regarding the compensation of its named executive officers every year, a policy that will remain in effect until the next stockholder vote on frequency, expected at the company's 2031 annual meeting of stockholders.

Management Comments

• The Board of Directors has determined that the Company will conduct future stockholder advisory votes regarding the compensation of the Company's named executive officers every year, consistent with the results of the advisory vote and the Company's recommendation.

Industry Context

The change in auditor reflects a common occurrence in the accounting industry where mergers and acquisitions among accounting firms lead to changes in client relationships. The robust shareholder participation and approval of governance matters, including director elections and executive compensation, indicate standard corporate governance practices for a publicly traded company.

Comparison to Industry Standards

• The transition of the audit firm due to an acquisition (Marcum's attest business by CBIZ CPAs) is a common event in the accounting industry, aligning with typical market consolidation trends among professional services firms.
• The high quorum of 82.2% at the annual meeting demonstrates strong shareholder engagement, which is generally considered a positive indicator of corporate governance compared to industry averages.
• The overwhelming approval of director nominees and executive compensation, along with the adoption of annual Say-on-Pay votes, aligns with best practices in corporate governance and shareholder alignment seen across many public companies, particularly those listed on Nasdaq.

Corporate Governance

Stakeholder Impact

• Shareholders: Confirmed board leadership, approved executive compensation, and established annual advisory votes on compensation, enhancing their oversight. The auditor change is a routine event not indicative of financial issues.
• Employees: Executive compensation practices were affirmed, which may impact morale and retention of key personnel.
• Auditors: Marcum LLP concluded its engagement, and CBIZ CPAs P.C. commenced its role, reflecting a business transition in the accounting sector.

Next Steps

• CBIZ CPAs P.C. will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The company will conduct future stockholder advisory votes regarding executive compensation annually.
• The next stockholder vote on the frequency of executive compensation advisory votes is expected at the 2031 annual meeting.

Key Dates

Recommendation

Keywords

Skye Bioscience, SKYE, SEC Filing, Form 8-K, Auditor Change, Independent Accountant, Marcum LLP, CBIZ CPAs P.C., Annual Meeting, Stockholder Vote, Director Election, Executive Compensation, Corporate Governance, Audit Firm